

CSD/BSE&NSE/BM/2022-23
May 9, 2022

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 9, 2022, approved the following along with other business matters.

1. Financial Results

Taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.

2. 2nd Interim Dividend

- a) The Board has declared 2nd Interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22.
- b) The Board has approved the **Record Date i.e., 17th May, 2022** notified earlier by the Company for the purpose of payment of dividend to the eligible shareholders.
- c) The above said dividend will be paid on and from 25th May, 2022, subject to deduction of tax at source.

Suven Pharmaceuticals Limited

3. e-Annual General Meeting and Date of closure of transfer books

- a) The 4th e-Annual General Meeting of the members of the Company will be held on Thursday, August 18, 2022 through VC/ OAVM.

- b) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from August 16, 2022 to August 18, 2022 (both days inclusive) for the purpose of 4th Annual General Meeting of the Company.

Further, we are enclosing herewith the following documents:

- 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2022 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement.
- 2) Auditor's Reports on the financial results as mentioned above
- 3) Declaration in respect of Audit Reports with unmodified opinion and
- 4) A copy of the News Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read 'K Hanumantha Rao', is written over a horizontal line.

K Hanumantha Rao
Company Secretary

Encl: as above



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & TWELVE MONTHS ENDED
31st MARCH ' 2022.

Rs. In Lakhs

PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended	
		31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	36,384.72	39,158.53	25,916.48	132,022.21	100,971.85
	Other Income	13,439.58	927.43	329.82	18,778.80	1,423.70
	Total income	49,824.30	40,085.96	26,246.30	150,801.01	102,395.55
2	Expenses					
	a) Cost of materials consumed	13,027.81	11,847.97	8,737.46	45,945.64	31,031.50
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,994.03)	96.07	398.28	(6,035.21)	(837.30)
	d) Employee benefits expense	3,112.20	2,500.87	1,651.27	10,048.39	7,623.30
	e) R & D expense	214.42	218.85	150.63	1,035.45	1,105.75
	f) Finance costs	218.87	74.17	187.03	623.10	914.37
	g) Depreciation and amortisation expenses	1,042.08	1,050.60	831.47	3,909.71	3,163.58
	h) Manufacturing Expenses	4,434.34	4,625.81	4,468.31	17,318.86	13,378.94
	i) Other Expenses	1,833.11	1,266.16	1,141.26	5,710.25	4,617.49
	Total expenses	21,888.80	21,680.50	17,565.71	78,556.19	60,997.63
3	Profit before exceptional items & Tax (1-2)	27,935.50	18,405.46	8,680.59	72,244.82	41,397.92
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	27,935.50	18,405.46	8,680.59	72,244.82	41,397.92
6	Tax Expenses					
	a) Current tax	5,148.01	4,620.66	1,834.65	15,763.03	10,171.51
	b) Deferred tax	341.02	85.27	400.73	671.91	361.72
7	Net Profit/ (Loss) for the period/year (5-6)	22,446.47	13,699.53	6,445.21	55,809.88	30,864.69
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(18.06)	(27.95)	(29.87)	(101.95)	(111.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.55	7.03	7.52	25.66	28.15
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(13.51)	(20.92)	(22.35)	(76.29)	(83.70)
9	Total Comprehensive Income for the period (7+8)	22,432.96	13,678.61	6,422.86	55,733.59	30,780.99
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
11	Other Equity	-	-	-	149,523.67	103,972.68
12	Earning Per Share (EPS)-Face value of Rs.1/- each)					
	a) Basic	8.82	5.38	2.53	21.92	12.12
	b) Diluted	8.82	5.38	2.53	21.92	12.12
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



PART - II		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended	
		31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	36,384.72	39,158.53	25,916.48	132,022.21	100,971.85
	Other Income	1,687.12	6,468.51	329.82	9,238.03	1,423.70
	Total income	38,071.84	45,627.04	26,246.30	141,260.24	102,395.55
2	Expenses					
	a) Cost of materials consumed	13,027.81	11,847.97	8,737.46	45,945.64	31,031.50
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,994.03)	96.07	398.28	(6,035.21)	(837.30)
	d) Employee benefits expense	3,112.20	2,500.87	1,651.27	10,048.39	7,623.30
	e) R & D expense	214.42	218.85	150.63	1,035.45	1,105.75
	f) Finance costs	218.87	74.17	187.03	623.10	914.37
	g) Depreciation and amortisation expense	1,042.08	1,050.60	831.47	3,909.71	3,163.58
	h) Manufacturing Expenses	4,434.34	4,625.81	4,468.31	17,318.86	13,378.94
	i) Other Expenses	1,887.94	1,266.91	1,141.48	5,766.55	4,621.60
	Total expenses	21,943.63	21,681.25	17,565.93	78,612.49	61,001.74
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	16,128.21	23,945.79	8,680.37	62,647.75	41,393.81
4	Add : Share of profit/(Loss) of Associates.	-	-	1,866.60	4,111.23	5,373.60
5	Profit before exceptional items , Tax (3+4)	16,128.21	23,945.79	10,546.97	66,758.98	46,767.41
6	Exceptional Items	-	-	-	-	-
7	Profit before Tax (5-6)	16,128.21	23,945.79	10,546.97	66,758.98	46,767.41
8	Tax Expenses					
	a) Current tax	5,964.54	6,843.36	1,834.65	19,040.47	10,171.51
	b) Deferred tax	996.87	1,095.53	400.73	2,338.02	361.72
9	Net Profit/ (Loss) for the period/year(7-8)	9,166.80	16,006.90	8,311.59	45,380.49	36,234.18
10	Other Comprehensive Income					
10.a	(i) Items that will not be reclassified to profit or loss	(18.06)	(27.95)	(29.87)	(101.95)	(111.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.55	7.03	7.52	25.66	28.15
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(13.51)	(20.92)	(22.35)	(76.29)	(83.70)
11	Total Comprehensive Income for the period (9 + 10)	9,153.29	15,985.98	8,289.24	45,304.20	36,150.48
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
13	Other Equity	-	-	-	150,172.39	115,535.18
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)					
	a) Basic -	3.60	6.29	3.27	17.83	14.23
	b) Diluted	3.60	6.29	3.27	17.83	14.23
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9 May,2022 . The above results for the year ended 31st March 2022 has been audited and for the quarter ended 31st Mar2022 has been reviewed by the statutory auditors of the company
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma,Inc.,USA.
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary , Suven Pharma , Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments , increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability.
 - 6) The other Income (Standalone figures) for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q3 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such Dividend by our subsidiary.
 - 7) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13 th Dec,2021. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar'2022.
 - 8) The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22.
 - 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.
 - 10) Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt. Ltd. an SEZ company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company w.e.f. 22 April 2022.

For SUVEN PHARMACEUTICALS LTD



VENKAT JASTI
Managing Director
DIN: 00278028

Place : Hyderabad
Date : 9th May ' 2022



Statement of Assets & Liabilities


Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
	Audited	Audited	Audited	Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	53,055.18	43,706.51	53,055.18	43,706.51
(b) Capital Work-in-Progress	2,999.38	9,614.91	2,999.38	9,614.91
(c) Other Intangible Assets	223.64	241.75	223.64	241.75
(d) Intangible assets under development	-	17.30	-	17.30
(e) Right of use of assets	140.56	167.53	140.56	167.53
(f) Financial Assets				
I. Investments	11,867.29	24,564.73	11,709.67	36,119.40
II. Loans	6.95	6.20	6.95	6.20
III. Other Financial Assets	539.21	495.18	1,269.59	495.18
(g) Deferred tax assets (net)	-	-	-	-
(h) Other non current assets	760.56	599.21	760.56	599.21
Total Non-Current assets	69,592.77	79,413.32	70,165.53	90,967.99
2 Current assets				
(a) Inventories	28,341.73	20,108.04	28,341.73	20,108.04
(b) Financial Assets			-	-
I. Investments	48,122.24	18,059.38	48,122.24	18,059.38
II. Trade Receivables	23,637.23	10,238.22	23,637.23	10,238.22
III. Cash and Cash equivalents	3,021.05	709.14	4,456.38	718.22
IV. Bank balances other than (III) above	274.20	247.10	274.20	247.10
V. Loans	18.63	21.78	18.63	21.78
VI. Other Financial assets	-	-	-	-
(c) Current Tax asset (net)	-	224.67	-	224.67
(d) Other current assets	7,480.94	6,861.11	7,942.79	6,861.11
Total Current assets	110,896.02	56,469.44	112,793.20	56,478.52
TOTAL - ASSETS	180,488.79	135,882.76	182,958.73	147,446.51
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	149,523.67	103,972.68	150,172.39	115,535.18
Equity attributable to owners of the company	152,069.32	106,518.33	152,718.04	118,080.83
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	46.29	73.90	46.29	73.90
II. Borrowings	2,844.04	3,559.09	2,844.04	3,559.09
(b) Provisions	889.45	664.60	889.45	664.60
(c) Deferred tax Liabilities (net)	3,739.55	3,093.29	5,431.51	3,093.29
(d) Other non current liabilities	-	-	-	-
Total non-current liabilities	7,519.33	7,390.88	9,211.29	7,390.88
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	109.09	106.82	109.09	106.82
II. Borrowings	6,713.31	10,563.76	6,713.31	10,563.76
III. Trade payables			-	-
a) To Micro & Small Enterprises	200.20	996.25	200.20	996.25
b) Other than Micro & Small Enterprises	10,389.85	7,296.89	10,389.85	7,296.89
IV. Other Financial Liabilities	2,126.01	2,522.75	2,255.27	2,524.00
(b) Current Tax liabilities (Net)	364.22	-	364.22	-
(c) Provision Employee benefits	407.53	260.72	407.53	260.72
(d) Other Current liabilities	589.93	226.36	589.93	226.36
Total Current liabilities	20,900.14	21,973.55	21,029.40	21,974.80
Total Liabilities	28,419.47	29,364.43	30,240.69	29,365.68
TOTAL - EQUITY AND LIABILITIES	180,488.79	135,882.76	182,958.73	147,446.51

For Suven pharmaceuticals Ltd

 Place: Hyderabad
 Date: 9th May, 2022


 Venkat Jasti
 Managing Director

SUVEN PHARMACEUTICALS LIMITED			
Standalone Statement of Cash flows for the period ended 31st March, 2022			
(All amounts in Indian Rupees In Lakhs, unless otherwise stated)			
Particulars		For the year ended 31st March 2022	For the year ended 31st March 2021
A. Cash flow from operating activities			
Profit before tax		72,244.82	41,397.92
Adjustments :			
Depreciation and amortisation expense		3,825.50	3,122.07
Interest Income		(6.86)	(26.79)
Finance Cost		623.10	914.37
Gain on sale of Current Investment		(820.31)	(332.77)
Dividend received from WOS		(15,081.85)	-
Debit balances writtenoff		-	72.16
Effects of foreign exchange rates (Unrealized)		442.01	(97.56)
Loss/(Profit) on disposal of Property,plant & equipment		(0.06)	(3.36)
Operating profit before working capital changes		61,226.35	45,046.06
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		(13,608.80)	1,336.08
Inventories		(8,233.69)	(2,620.82)
Other non current assets		26.97	(78.95)
Other current assets		(621.56)	(1,269.92)
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		2,320.35	1,194.52
Long term provisions		224.85	(166.86)
Short term provision		44.86	(102.78)
Other financial liabilities		420.66	654.28
Other current liabilities		363.60	(164.48)
Cash generated from operating activities		42,163.59	43,827.12
Income taxes paid (net of refunds)		(15,174.14)	(10,943.58)
Net Cash flows from operating activities	(A)	26,989.45	32,883.54
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(7,518.67)	(11,084.60)
Proceeds from sale of Property, plant & equipment		0.06	3.36
Changes in Investments		12,697.44	-
Dividend received from WOS		15,081.85	-
Fixed deposits/margin money-placed/matured		(44.03)	(20.31)
Sale/(purchase) of mutual funds		(29,242.55)	(14,659.28)
Bank balances not considered as cash and cash equivalents		(10.47)	(5.12)
Net cash flow from /(used in) investing activities	(B)	(9,036.37)	(25,765.95)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(959.73)	(5,472.65)
(Repayment)/Proceeds from short term borrowings		(3,859.71)	1,230.17
Other non current financial assets		(0.75)	(0.20)
Other current financial assets		3.15	(1.39)
Changes In Lease Liability		(25.33)	89.12
Finance Cost		(623.10)	(892.36)
Interest received		6.86	26.79
tax)		(10,182.60)	(2,545.65)
Net cash flow from /(used In) financing activities	(C)	(15,641.21)	(7,566.17)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	2,311.87	(448.57)
Cash and cash equivalents as at the beginning of the year		709.14	1,157.68
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.04	0.03
Cash and cash equivalents at the end of the year		3,021.04	709.14
For Suven Pharmaceuticals Ltd  Venkateswarlu Jasti Managing Director DIN: 00278028			
Place : Hyderabad Date : 09th May 2022			



SUVEN PHARMACEUTICALS LIMITED			
Consolidated Statement of Cash flows for the year ended 31st March, 2022			
(All amounts in Indian Rupees In Lakhs, unless otherwise stated)			
Particulars		For the year ended 31st March 2022	For the year ended 31st March 2021
A. Cash flow from operating activities			
Profit before tax		66,758.98	46,767.41
Adjustments :			
Depreciation and amortisation expense		3,825.50	3,122.07
Interest Income		(6.86)	(26.79)
Finance Cost		623.10	914.37
Gain on sale of Current Investment		(820.31)	(332.77)
Debit balances writtenoff		-	72.16
Effects of foreign exchange rates (Unrealized)		442.01	(97.56)
Loss/(Profit) on disposal of Property, plant & equipment		(0.06)	(3.36)
Operating profit before working capital changes		70,822.36	50,415.54
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		(13,608.80)	1,336.08
Inventories		(8,233.69)	(2,620.82)
Other non current assets		26.97	(78.95)
Other current assets		(1,083.41)	(1,269.55)
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		2,320.35	1,194.52
Long term provisions		224.85	(166.86)
Short term provision		44.86	(102.78)
Other financial liabilities		548.66	655.53
Other current liabilities		363.60	(164.48)
Cash generated from operating activities		51,425.75	49,198.23
Income taxes paid (net of refunds)		(18,425.73)	(10,943.58)
Net Cash flows from operating activities	(A)	33,000.02	38,254.65
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(7,518.67)	(11,084.60)
Proceeds from sale of Property, plant & equipment		0.06	3.36
Changes in Investments		24,409.74	(5,373.60)
Foreign currency translation reserve		(484.39)	(0.27)
Fixed deposits/margin money-placed/matured		(774.41)	(20.31)
Sale/(purchase) of mutual funds		(29,242.55)	(14,659.28)
Bank balances not considered as cash and cash equivalents		(10.47)	(5.12)
Net cash flow from /(used in) investing activities	(B)	(13,620.69)	(31,139.82)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(959.73)	(5,472.65)
(Repayment)/Proceeds from short term borrowings		(3,859.71)	1,230.17
Other non current financial assets		(0.75)	(0.20)
Other current financial assets		3.15	(1.39)
Changes In Lease Liability		(25.33)	89.12
Finance Cost		(623.10)	(892.36)
Interest received		6.86	26.79
tax)		(10,182.60)	(2,545.65)
Net cash flow from /(used In) financing activities	(C)	(15,641.21)	(7,566.17)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	3,738.12	(451.33)
Cash and cash equivalents as at the beginning of the year		718.22	1,169.53
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.04	0.03
Cash and cash equivalents at the end of the year		4,456.38	718.22

For Suven Pharmaceuticals Ltd

Venkateswarlu Jasti

Venkateswarlu Jasti

Managing Director

DIN: 00278028

Place : Hyderabad

Date : 09th May 2022





INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2022 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2022 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Consolidated Financial Results for the quarter and year ended March 31, 2022" of **SUVEN PHARMACEUTICALS LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") and its share of the net profit after tax and total comprehensive income of its associate company for the quarter and year ended March 31, 2022, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of the subsidiary and associate referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2022:

- (i) Includes the results of the following entities:


Name of the Company	Country	Relationship
SUVEN PHARMA INC	USA	Wholly Owned Subsidiary
RISING PHARMA HOLDINGS INC	USA	Associate*

*Till Q3 of FY 2021-22

- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group and its associate for the year ended March 31, 2022.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2022

With respect to the Consolidated Financial Results for the quarter ended March 31, 2022, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2022 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for



09/05/2022

the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2022

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (the “Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management’s Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent’s Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2022, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group, its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no



09/05/2022

realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associate are responsible for overseeing the financial reporting process of the Group and associate.


Auditor's Responsibilities for

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2022

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2022 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



09/05/2022

- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors .For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2022

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2022 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- Attention is drawn to Note 9 to the Statement which states that the Consolidated Financial



09/05/2022

Results includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year .Our report is not modified in respect of this matter.

- Attention is drawn to Note 9to the Statement, the figures for the corresponding quarter ended March 31, 2021 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2020. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2021. Our report is not modified in respect of this matter.
- The accompanying statement includes unaudited interim financial results and other unaudited financial information of the subsidiary, whose interim financial information reflect total assets of Rs.3210.4 Lakhs, total revenues of Rs.(9540.77) Lakhs and Rs.(11752.45) Lakhs for the year ended and quarter ended 31st March,2022 respectively and Net profit after tax of Rs.(10429.39) Lakhs and Rs.(6958.23) for the year ended and quarter ended March 31, 2022 respectively(including share of profits of its associate) , and Total comprehensive income of Rs.(10429.39) Lakhs and Rs.(6958.23) Lakhs for the year ended and quarter ended March 31, 2022 respectively (including share of profits of its associate) and Net cash flows of Rs. 1426.24 Lakhs for the year ended March 31, 2022 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor.
- Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.
- We draw attention to Note No 7 of the accompanying statement, where in the management has explained that, Suven Pharma Inc., the WOS of the Company has divested its entire stake (25% amounting to \$35.00 Mn) in Rising Pharma Holdings, Inc., USA on 13th December, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through a structured deal. As part of the structured deal, the WOS, Suven Pharma, Inc., has in the form of cash component received an amount of \$41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc. has ceased to be an associate w.e.f 13th December, 2021. Hence, the share of profits of associate have not been considered in the consolidated financial statements from the quarter ended 31st December, 2021.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)



AJAYKUMAR KOSARAJU

Partner

Membership No. 021989

UDIN: 22021989AIPWTL1949



Place: Hyderabad

Date: 9th May, 2022.

09/05/2022



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2022 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2022 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Year Ended March 31, 2022 and unaudited Standalone Financial Results for the Quarter Ended March 31, 2022 ("the Statement") of SUVEN PHARMACEUTICALS LIMITED ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2022:


- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive Income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2022

With respect to the Standalone Financial Results for the quarter ended March 31, 2022, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2022

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the



09/05/2022

Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2022 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the net profit and other comprehensive Income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and Fairview and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for

(a) Audit of the Standalone Financial Results for the year ended March 31, 2022

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2022 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



09/05/2022

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.



09/05/2022

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


(b) Review of the Standalone Financial Results for the quarter ended March 31, 2022

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2022 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- These standalone financial results incorporate the relevant returns of foreign branch audited by the other auditors specifically appointed for this purpose, whose financial information reflect total assets of Rs.158.72 lacs as at March 31, 2022 and total revenues of Rs.NIL for the year ended March 31, 2022, total net loss of Rs.833.96 lacs for year ended March 31, 2022
- Attention is drawn to Note 10 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the current financial year Our report is not modified in respect of this matter.
- Attention is drawn to Note 10 to the Statement, the figures for the corresponding quarter ended March 31, 2021 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2020. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2021. Our report is not modified in respect of this matter.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)


AJAYKUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 22021989AIPWOG4582



Place: Hyderabad
Date: May 9th, 2022.

09/05/2022

CSD/SE/BM/2022-23

May 9, 2022

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

.....

We hereby declare that the Statutory Auditors of the Company, M/s. Karvy & Co., (FRN: 001757S) Chartered Accountants have issued an Audit Reports with unmodified opinion on audited financial results of the company (Standalone and Consolidated) for the year ended 31st March, 2022.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



Venkateswarlu Jasti
Managing Director

Suven Pharmaceuticals Limited

NEWS RELEASE

HYDERABAD, INDIA (9 May' 2022) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 Mar' 2022. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 9 May' 2022 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Year ended	
	31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
Revenue from operations	3,638.47	3,915.85	2,591.65	13,202.22	10,097.19
Other Income	1,343.96	92.74	32.98	1,877.88	142.37
Total Income	4,982.43	4,008.60	2,624.63	15,080.10	10,239.56
EBITDA	2,919.65	1,953.02	969.91	7,677.76	4,547.59
EBITDA Margin	58.60%	48.72%	36.95%	50.91%	44.41%
EBIT	2,815.44	1,847.96	886.76	7,286.79	4,231.23
EBIT Margin	56.51%	46.10%	33.79%	48.32%	41.32%
Finance costs	21.89	7.42	18.70	62.31	91.44
Depreciation	104.21	105.06	83.15	390.97	316.36
Taxes	548.90	470.59	223.54	1,643.49	1,053.32
Taxes to PBT	19.65%	25.57%	25.75%	22.75%	25.44%
PAT (Standalone)	2,244.65	1,369.95	644.52	5,580.99	3,086.47
PAT Margin (Standalone)	45.05%	34.18%	24.56%	37.01%	30.14%
Associate Company	-	-	186.66	411.12	537.36
PAT (Consolidated)	916.68	1,600.69	831.16	4,538.05	3,623.42
PAT Margin (Consolidated)	18.40%	39.93%	31.67%	30.09%	35.39%
EPS (Standalore)	8.82	5.38	2.53	21.92	12.12
EPS (Consolidated)	3.60	6.29	3.27	17.83	14.23
Paid up share capital (Re.1/sh)	254.56	254.56	254.56	254.56	254.56

Growth Ratios

	31 Mar 22 to Quarter ended 31 Dec 21	31 Mar 22 to Quarter ended 31 Mar 21	Mar 22 to Year ended 31 Mar 21
Growth in income	24.29%	89.83%	47.27%
Growth in EBIDTA	49.49%	201.02%	68.83%
Growth in EBIT	52.35%	217.50%	72.21%
Growth in PAT Standalone	63.85%	248.27%	80.82%
Growth in PAT Consolidated	-42.73%	10.29%	25.24%

Suven Pharmaceuticals Limited

Operational Profitability	Quarter ending		Year ending	
	31-Mar-22	31-Dec-21	31-Mar-22	31-Mar-21
CDMO Revenue	3,638.47	3,915.85	13,202.22	10,097.19
Adjusted PAT	1,187.85	1,086.19	4,240.42	3,086.47
CDMO PAT/Income	32.65%	27.74%	32.12%	30.57%
Adjusted EBIDTA	1,862.85	1,669.26	6,337.20	4,547.59
CDMO EBIDTA/Income	51.20%	42.63%	48.00%	45.04%
Adjusted EBIT	1,640.19	1,515.02	5,778.61	4,231.23
CDMO EBIT/Income	45.08%	38.69%	43.77%	41.91%

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to \$35.00 Mn) in Rising Pharma Holdings, Inc., USA on 13 Dec 2021 and accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P w.e.f 13 Dec 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar 2022.
3. The Board has declared 2nd interim dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22.
4. Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt. Ltd. an SEZ company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company w.e.f. 22 April 2022.
5. The COVID-19 continuous to impact the business and research operations in India.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited